Program Outcomes
Evaluating, Measuring, and Identifying Patient Care Benefits and Cost Reduction

Kansas Medical Assistance Program
Retrospective Drug Utilization Review Provider Education and Intervention Program

Prepared by Christina Faulkner, PharmD, BCPS
Health Information Designs, LLC
Executive Summary

This Outcomes Assessment report prepared for the Kansas Medical Assistance Program shows the expected improvements in beneficiary health and cost savings from using retrospective drug utilization review and provider education to effect appropriate prescribing and utilization and, in turn, prevent adverse drug reactions and reduce costs in a targeted beneficiary population.

Program Summary

Long term daily treatment (e.g., 3 years or more) with acid-suppressing medications may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppression therapy have been reported in the literature and this diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.

Patients with vitamin B-12 deficiency may initially present with non-specific symptoms, such as fatigue, irritability and/or cognitive decline; however, the classic symptom is subacute combined degeneration of the dorsal and lateral columns of the spinal column due to demyelination. This causes weakness, ataxia and paresthesias which may progress to spasticity and paraplegia. There are also reports of increased risk of osteoporosis and gastric cancer. As stated earlier, initial symptoms may be very nonspecific and hard to quantify, so it is important that cyanocobalamin levels are monitored in those beneficiaries that have long term daily treatment with acid-suppressing agents.

Beneficiaries were selected by identifying those clients that had regular claims for proton pump inhibitors (e.g., had at least 85 days of therapy in 90 days) and were active in the fee-for-service program. A clinical pharmacist then reviewed each selected profile to verify long-term continuous acid suppression therapy and to determine if it was appropriate to send an educational letter to the prescriber.

Changes in Criteria Exceptions

At the 6-month evaluation post intervention, appropriate utilization was significantly improved in the target population. Six months after letters were mailed to the prescribers, all 8 of the original 8 beneficiaries had at least one claim for any drug and could be evaluated. Of those 8 beneficiaries, 62.5% of those who were previously found to meet the criteria no longer had the same therapy issue that their prescriber received a letter about. Based on changes in utilization, it is clinically probable that serious adverse outcomes were avoided, and drug therapy was reviewed and modified.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>PRE-Intervention</th>
<th>POST-Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Beneficiaries</td>
<td>Beneficiaries</td>
</tr>
<tr>
<td></td>
<td>with Letter</td>
<td>with Any Drug</td>
</tr>
<tr>
<td></td>
<td>Mailed</td>
<td>Claim</td>
</tr>
<tr>
<td>Long-term use of proton pump inhibitors and</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>potential for cyanocobalamin deficiency</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Background

Health Information Designs (HID), in coordination with Gainwell Technologies, currently performs retrospective drug utilization review (RetroDUR) for Kansas Medical Assistance Programs’ fee-for-service population. The total number of unique beneficiaries enrolled in the traditional Medicaid fee-for-service population in State Fiscal Year (SFY) 2020 (July 1, 2019 – June 30, 2020) was 19,558. Prescription claims for approximately 2,920 beneficiaries were processed each month in SFY 2020.

Beneficiary Identification and Prescriber Intervention

In an effort to promote appropriate prescribing and utilization of medications, HID identified beneficiaries who appeared to be on long-term daily acid suppression therapy and at risk for cyanocobalamin deficiency (September interventions). Once identified, educational letters were mailed to their prescribers. When more than one prescriber was attributed to pertinent claims on a patient profile, letters were mailed to all relevant prescribers.

While the intervention letter itself only addressed the medications included in the intervention, HID included a 6-month history of drug claims and diagnoses along with the letter. Prescribers had the opportunity to review the entire beneficiary drug and diagnosis history and make changes to therapies based upon this information. For this reason, whenever intervention letters are sent to prescribers, the impact on total drug utilization should be measured. Therefore, total drug utilization in the targeted population was evaluated for 6 months before and after intervention letters were mailed to determine any change in drug cost.

Analysis Methodology

Each month HID evaluates Kansas Medical Assistance Program pharmacy claims data against thousands of proprietary criteria. The criteria are developed and maintained by HID clinical pharmacists who review package insert updates, as well as medical literature, to develop the criteria.

Criteria Evaluated

The following criteria were reviewed for the intervention letters mailed in September 2020.

- **Therapeutic Appropriateness:**
  - Long term utilization of acid suppressing medications and risk for cyanocobalamin deficiency.

Beneficiary Selection

Beneficiaries were selected by identifying those clients that had regular claims for proton pump inhibitors (e.g., had at least 85 days of therapy in 90 days) and were active in the fee-for-service program. A clinical pharmacist then reviewed each selected profile to verify long-term continuous acid suppression therapy and to determine if it was appropriate to send an educational letter to the prescriber.
After beneficiaries were selected for intervention, educational intervention letters—including a complete drug and diagnosis history profile listing all pharmacy and available diagnosis claims data for the past 6 months—were mailed to the appropriate prescribers. (Prior to mailing, generated letters undergo a quality assurance process. Some letters are not mailed due to various reasons, including missing or invalid prescriber addresses.)

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Beneficiaries Reviewed</th>
<th>Beneficiaries Initially Selected for Intervention</th>
<th>Letters Generated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term use of proton pump inhibitors and potential for cyanocobalamin deficiency</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

Once a beneficiary was selected for intervention, the criteria were suppressed by the DUR system for that beneficiary for 6 months.

**Prescriber Response Tabulation**

The intervention letter and drug history profile included a response form that allowed the prescriber to provide feedback and enabled HID to determine whether any action would be taken in response to the letter. The response form includes standard responses printed on the form that allow the prescriber to check a box for the response that best fits their intended action, as well as space for written comments from the prescriber.

The prescribers were encouraged to return the response forms using the self-addressed stamped envelope included with the intervention letter or via fax. HID tracked all response forms returned as well as all written-in comments from prescribers for evaluation. See the **Results** section for these numbers.

**Evaluation of Changes in Criteria Exceptions**

In an effort to determine the impact of the intervention letters independent of prescriber responses, beneficiary claims were evaluated 6 months after letters were mailed. Since the letters were mailed in September 2020 (with a 2-week null period to allow for letters to be mailed and received taken into account), the 6-month follow up was performed in April 2021. HID first determined how many of the selected beneficiaries continued to have Medicaid benefits and still had active eligibility by determining how many had any claim for any drug in the post-intervention period (October 2020 – April 2021). Following that, HID determined who still met the same criteria after the post-intervention period, in April 2021. See the **Results** section for these numbers.

**Limitations**

One limitation resulted from the fact that no eligibility data was available to determine whether beneficiaries continued to be eligible for Medicaid for the full 6 months before and after intervention letters were mailed. Therefore, as a means to test for Medicaid eligibility when calculating cost avoidance, HID determined how many beneficiaries had any claim for any drug...
during both the pre-intervention period and the post-intervention period. Those beneficiaries who did not have claims in both periods were not included in the follow-up analysis. It is possible that some patients who had Medicaid eligibility may have been excluded from the follow-up analysis if they had no recent pharmacy claims.

The same eligibility process was applied to the changes in criteria exceptions.

Results

Prescriber Responses to Intervention Letters

A total of 4 coded responses were received from the prescribers who were sent an intervention letter, for a response rate of 50%. Coded responses are shown in the table below.

<table>
<thead>
<tr>
<th>Response</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefits of the drug outweigh the risks</td>
<td>2</td>
</tr>
<tr>
<td>Prescriber states problem is insignificant; no change in therapy required</td>
<td>1</td>
</tr>
<tr>
<td>Prescriber tried to modify therapy; symptoms recurred</td>
<td>1</td>
</tr>
</tbody>
</table>

Total Responses 4

Prescriber Feedback on Intervention Letters

In addition to being able to provide information about their course of action following receipt of the intervention letter, prescribers are also able to provide additional feedback on intervention letters. Out of the 4 coded responses received, 4 provided additional feedback. A total of 75% ranked the letters as “Useful”, with 1 ranking it as “Neutral”.

Results Discussion

Within the targeted beneficiary population, improvements in utilization were noted. Six months after intervention letters were mailed, the total population of 8 patients had enough data available to evaluate. Of these patients, all of whom met criteria prior to the mailing of prescriber letters, 62.5% no longer met the same criteria 6 months after the letters were mailed.

All drug claims data and some diagnosis data are available for analysis. Any diagnosis data available is processed along with the pharmacy claims data to provide as complete a drug and diagnosis history as possible for each beneficiary. Medical data that includes the cost associated with hospitalization, doctor visits, and emergency room visits is not analyzed as part of the RetroDUR program. However, it is suspected that by improving utilization and the monitoring for adverse events, other medical-associated costs due to adverse drug effects would be reduced, in addition to the reduction in drug expenditures.
Conclusion

The long-term prescribing and utilization of acid suppressing drugs and increased risk for cyanocobalamin deficiency was reevaluated after intervention letters were mailed to prescribers for targeted beneficiaries. For beneficiaries with data available for follow-up 6 months after letters were mailed (8 beneficiaries), 62.5% of them no longer met the same criteria (5 beneficiaries).

Prescribers were encouraged to return response forms to indicate their intended action following the receipt of the intervention letter and patient profile. The response rate was 50% for this intervention.